These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11917241)

  • 1. Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
    Zala C; Salomon H; Ochoa C; Kijak G; Federico A; Perez H; Montaner JS; Cahn P
    J Acquir Immune Defic Syndr; 2002 Apr; 29(4):368-73. PubMed ID: 11917241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
    Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
    Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
    García F; Knobel H; Sambeat MA; Arrizabalaga J; Aranda M; Romeu J; Dalmau D; Segura F; Gomez-Sirvent JL; Ferrer E; Cruceta A; Gallart T; Pumarola T; Miró JM; Gatell JM;
    AIDS; 2000 Nov; 14(16):2485-94. PubMed ID: 11101059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
    Reliquet V; Ferré V; Hascoet C; Besnier JM; Bellein V; Arvieux C; Molina JM; Breux JP; Zucman D; Rozenbaum W; Allavena C; Raffi F;
    Antivir Ther; 1999; 4 Suppl 3():83-4. PubMed ID: 16021876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
    AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
    Moore RD; Wong WM; Keruly JC; McArthur JC
    AIDS; 2000 Feb; 14(3):273-8. PubMed ID: 10716503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
    AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
    King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
    Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
    French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
    HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
    Moore RD; Keruly JC; Chaisson RE
    AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
    HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
    Zala C; Salomón H; Cahn P
    Antivir Ther; 1999; 4 Suppl 3():95-9. PubMed ID: 16021880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients.
    Raffi F; Reliquet V; Auger S; Besnier JM; Chennebault JM; Billaud E; Michelet C; Perre P; Lafeuillade A; May T; Billaudel S
    AIDS; 1998 Oct; 12(15):1999-2005. PubMed ID: 9814868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
    Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
    Raffi F; Reliquet V; Ferré V; Arvieux C; Hascoet C; Bellein V; Besnier JM; Breux JP; Garré M; May T; Molina JM; Perré P; Raguin G; Rozenbaum W; Zucman D
    Antivir Ther; 2000 Dec; 5(4):267-72. PubMed ID: 11142621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study.
    Rutschmann OT; Vernazza PL; Bucher HC; Opravil M; Ledergerber B; Telenti A; Malinverni R; Bernasconi E; Fagard C; Leduc D; Perrin L; Hirschel B
    AIDS; 2000 Sep; 14(14):2145-51. PubMed ID: 11061656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.